Description
The Food and Drug Administration (FDA) is seeking information from Venture Capital (VC) firms regarding their interest in and requirements for a novel contract vehicle that would enable portfolio companies to compete directly for FDA contracts and task orders. The FDA recognizes that many breakthrough technologies and innovative solutions relevant to its public health mission are being developed by companies within VC portfolios. These companies often possess cutting-edge capabilities in areas such as artificial intelligence, biotechnology, medical devices, and regulatory technology that could significantly benefit FDA operations and the broader public health ecosystem.
The key aspects of this opportunity include:
• Establishing direct contractual relationships with qualified VC firms
• Enabling any company within an approved firm's portfolio to compete for and receive task orders under the vehicle
• Streamlining the procurement process for innovative technologies and services
• Providing a scalable mechanism for engaging with the startup ecosystem
• Maintaining appropriate oversight and compliance with federal acquisition regulations
Attached files
Contact
Phillip Frame